10-Q: Jasper Therapeutics Q1 2026: Reduced R&D Spending, Increased Cash Burn

Jasper Therapeutics reports a significant decrease in R&D expenses for Q1 2026, alongside a substantial increase in cash burn, while facing ongoing litigation and substantial doubt about its ability to continue as a going concern.

Summary

• Jasper Therapeutics' Q1 2026 results show a significant reduction in operating expenses, primarily driven by a 64% decrease in research and development (R&D) costs, totaling $5.8 million compared to $16.2 million in Q1 2025.
• General and administrative expenses also saw a slight decrease of 9% to $5.1 million from $5.6 million in the prior year period.
• Despite reduced spending, the company's net loss widened to $1.2 million ($0.04 per share) in Q1 2026, compared to a net loss of $21.2 million ($1.41 per share) in Q1 2025, largely due to a significant positive change in the fair value of warrant liability in the current year.
• Cash and cash equivalents decreased to $14.1 million as of March 31, 2026, from $28.7 million as of December 31, 2025, indicating an increased cash burn rate.
• The company continues to face substantial doubt about its ability to continue as a going concern, necessitating active pursuit of additional capital.
• Ongoing litigation, including a shareholder class action and derivative complaints, remains a factor, though the company believes these claims are without merit.
• Clinical development efforts for briquilimab in Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU) are ongoing, with updated positive preliminary data presented from the BEACON and SPOTLIGHT studies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the substantial doubt about the company's going concern status, increased cash burn, and ongoing litigation, despite some positive clinical data.

Positives

• Positive preliminary data from the Phase 1b/2a BEACON study in CSU showed rapid onset of clinical efficacy with briquilimab, including 100% complete responses at the 240mg dose level through 8 weeks in earlier cohorts.
• Updated data from the BEACON study in CSU in January 2026 showed continued favorable safety and efficacy, with 83% of participants achieving a clinical response by week 3 and 67% reporting a complete response at 12 weeks in the 240mg/180mg Q8W cohort.
• Positive preliminary data from the Phase 1b/2a SPOTLIGHT study in CIndU demonstrated high response rates, with 93% of participants achieving a clinical response across 40mg and 120mg cohorts, and 100% achieving a clinical response in the 180mg single dose cohort.
• The ETESIAN study in asthma showed briquilimab reduced allergen-induced Late Asthmatic Response (LAR) and sputum eosinophils, supporting further development in the broader asthma population.
• The company has $263.5 million available under its shelf registration statement and $93.5 million remaining under its ATM offering as of March 31, 2026, providing potential avenues for future funding.
• The change in fair value of warrant liability resulted in a significant positive impact on net income for the quarter.

Negatives

• Net loss for the three months ended March 31, 2026 was $1.2 million, compared to $21.2 million in the prior year period, but this was largely due to a favorable change in warrant liability valuation, not improved operational performance.
• Cash and cash equivalents decreased significantly from $28.7 million at the end of 2025 to $14.1 million at the end of Q1 2026, indicating a substantial increase in cash burn.
• The company has substantial accumulated deficit of $317.8 million as of March 31, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within one year from the issuance date of the financial statements.
• Research and development expenses decreased by 64% to $5.8 million, indicating a potential slowdown in development activities, possibly due to resource constraints.
• The company reported an atypical absence of UAS7 reduction in some CSU patients in the 240mg Q8W and 240mg/180mg Q8W dose cohorts of the BEACON study, leading to an investigation.
• The company is facing shareholder class action and derivative lawsuits, although it believes the claims are without merit.

Risks

• The company has incurred significant net losses and negative operating cash flows since inception, raising substantial doubt about its ability to continue as a going concern.
• The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• The company will need substantial additional funding, which may not be available on acceptable terms, or at all.
• If the company is unable to raise capital when needed, it may be forced to delay, reduce or eliminate research and product development programs or future commercialization efforts.
• The company faces risks related to the development, regulatory approval, manufacturing, and commercialization of its product candidates.
• The market price of the company's common stock is volatile and may decline significantly.
• The company is subject to ongoing shareholder class action and derivative lawsuits.
• The company's license agreements may be terminated if payment or other obligations are not met.
• The company's ability to raise additional funds may be adversely impacted by negative global economic conditions and disruptions in credit and financial markets.

Future Outlook

The company expects to continue to incur substantial losses and requires significant additional funding to continue operations and product development. Future financing needs will depend on R&D progress, regulatory approvals, commercialization costs, and intellectual property expenses. The company is actively seeking additional capital through equity or debt financings, collaborations, or a combination thereof.

Management Comments

• Management expects that the existing cash and cash equivalents will not be sufficient to fund the Company's operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements.
• Management expects to finance the Company's future cash needs through equity or debt financings, collaborations or a combination of these approaches, and given the imminent need for additional funding to continue to fund operations in the near-term, the Company is actively seeking additional capital to extend the cash runway.
• The Company believes the claims raised in these lawsuits are without merit, and intends to defend these matters vigorously.

Industry Context

StockSavvy.ai notes that Jasper Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector. The significant reduction in R&D spending, while potentially a strategic move to conserve cash, could impact the pace of development compared to peers who may be investing more heavily. The company's focus on mast cell-driven diseases positions it within a niche but growing area of therapeutic development.

Comparison to Industry Standards

• Jasper Therapeutics' R&D expenses as a percentage of total operating expenses for Q1 2026 were approximately 53% ($5.8M / $10.9M), a significant decrease from approximately 74% ($16.2M / $21.8M) in Q1 2025, indicating a shift in resource allocation.
• The company's cash burn rate in Q1 2026 was approximately $14.5 million, which is substantial for a clinical-stage company with no approved products. This burn rate is higher than the net loss of $1.2 million, primarily due to the favorable change in warrant liability valuation.
• The company's reliance on future financings is common among clinical-stage biotechs, but the explicit statement of 'substantial doubt about its ability to continue as a going concern' highlights a more precarious financial position than many industry peers.
• The positive preliminary clinical data for briquilimab in CSU and CIndU aligns with industry trends of developing targeted therapies for specific patient populations, but the investigation into efficacy in certain cohorts suggests potential challenges in trial execution or patient selection, which are critical for regulatory approval and market acceptance.

Legal Proceedings

• A shareholder class action complaint (Grant v. Jasper Therapeutics, Inc., et al.) alleges material misstatements or omissions related to ongoing clinical trials of briquilimab.
• Shareholder derivative complaints (Bardauskas v. Martell, et al. and Walsh v. Martell, et al.) name current and former officers and directors and allege claims related to the class action allegations.
• The company believes the claims raised in these lawsuits are without merit and intends to defend them vigorously.

Related Party Transactions

• In Q1 2024, a senior executive joined the board of an IT service provider used by the company. In Q1 2026 and Q1 2025, the company incurred $0.3 million and $0.2 million, respectively, for IT support services from this provider.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and volatility in stock price.
• Employees may be impacted by the company's financial position and the need for potential future cost reductions.
• Creditors and suppliers may face risks if the company is unable to secure sufficient funding to continue operations.

Next Steps

• Advance briquilimab clinical development programs in chronic urticaria.
• Evaluate the competitive landscape, potential for strategic partnerships, and capital availability for advancing future clinical studies in asthma.
• Continue to broaden the pipeline with additional mast cell indications and next-generation products.
• Actively seek additional capital to extend the cash runway.
• Integrate clinical operations and development recommendations on patient enrollment processes into the planned Phase 2b/3 CSU study.

Key Dates

Recommendation

While Jasper Therapeutics shows promising clinical data for briquilimab in specific indications, the significant financial concerns, including substantial doubt about its going concern status and increased cash burn, coupled with ongoing litigation, warrant a cautious approach. The company's ability to secure future funding is critical. Investors should hold and monitor upcoming clinical trial results and financing activities closely.

Keywords

Jasper Therapeutics, 10-Q, Biotechnology, Clinical Stage, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Asthma, Briquilimab, Mast Cell Driven Diseases, SEC Filing, Financial Results, R&D Expenses, Cash Burn, Going Concern, Warrant Liability